Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma.

Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC

Assessment of serum GP73, AFP-L3, AFP and AFU detection in the diagnosis of hepatocellular carcinoma

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Lens Culinaris Agglutinin-Reactive Fraction of Alpha-Fetoprotein As A Marker of Prognosis and A Monitor of Recurrence of Hepatocellular Carcinoma after Curative Liver Resection

The Prognostic Values of Serum Markers in Hepatocellular Carcinoma after Invasive Therapies Based on Real‐world Data

Function of AFP and DCP in Evaluating the Prognosis of Hepatocarcinoma

Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: an Analysis of 4792 Patients

Clinical Value of Alpha-Fetoprotein Heterogeneity 3, Golgin 73 and Glypican 3 in Diagnosis of Primary Hepatic Cancer

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma

Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis

α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis

Diagnostic Values of Alpha-Fetoprotein, Dickkopf-1, and Osteopontin for Hepatocellular Carcinoma

Value of GPC3, GP73, AFP-L3 and AFP detection in the diagnosis of primary hepatic carcinoma